New Analysis Of UPLIZNA Phase 3 Trial Data Demonstrates Importance Of Reducing Plasmablasts To Help Prevent Neuromyelitis Optica Spectrum Disorder Attacks
-- Separate analysis also being presented at ECTRIMS 2022 reinforces the efficacy of UPLIZNA in patients with genetic variations --